Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Pharmagen, Inc.
SILVER SPRING, Md., May 6, 2014 /PRNewswire/ -- Pharmagen, Inc. (OTCPINK: PHRX) (the "Company" or "Pharmagen") today announced that Frederick W. Mundt has accepted the position of Senior Vice President of Sales. Frederick ("Fred") begin on May 2, 2014. Fred's addition is key to building out the Pharmagen Team. Fred brings a wealth of knowledge and experience in sales, business development and operational leadership. Highlights of Fred's experience includes: nine years with Astellas Pharmaceuticals, ten years with Ortho Biotech Inc., and most recently he served as Director, Commercial Deployment and Alignments with Quest Diagnostics.
"Fred's rich experience in direct sales organizations as well as his most recent role at Quest Diagnostics where he was integral in building out their sales capacity and processes made Fred the clear leader amongst a strong talent pool provided by Tim Tolan, Senior Partner at Sandford Rose Associates – The Toland Group. We conducted an intricate selection process and Fred's skills and professionalism, especially his detailed understanding in how to build a sales organization were the determinate factors in his selection," says Boyd Relac, Chief Operating Officer. Relac continued, "We have a plan built for Fred to hit the ground running immediately gaining incremental sales momentum for Pharmagen so we can quickly begin hiring field sales professionals to call across and expand our customer base of hospitals, and physicians who conduct in-office dispensing of non-script pharmaceuticals as well as prescription based referrals. I really want to thank Tim Tolan who sourced a strong field of candidates which we are continuing to consider as we build a professional sales capacity and especially for bringing Fred to Pharmagen."
Commenting on his new role, Mr. Mundt stated, "This is a very exciting time to be joining Pharmagen as they are poised for growth. The executive team is taking all of the necessary steps to be the leader in specialty drug, compounding and admix delivery. This is a great opportunity for me to leverage my experience building and developing commercial sales teams and to drive incremental sales growth for company. Joining the leadership team is truly an honor and I look forward to our bright future."
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. offers innovative solutions to the nations sterile pharmaceutical crisis. With a multi-solution approach, Pharmagen is helping to meet the demand of the health provider market through independent wholesale, compounding, and IT solutions. Nationally focused, Pharmagen is a distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
©2012 PR Newswire. All Rights Reserved.